PRXL $20 PAREXEL has been selected as one of two strategic partners by UCB (PRXL) 20.41 +0.48 : Co has been selected as one of two strategic partners by UCB to provide clinical development services worldwide. The agreement is effective for all of UCB's new clinical study programs on a global basis. Through the strategic partnership, UCB will receive the benefits of PAREXEL's proven clinical processes through all phases of development, which are supported by its market-leading eClinical technology platform. UCB will also leverage PAREXEL's consulting expertise in regulatory affairs and commercialization.